A Single-Arm, Open-Label, Phase 1/2 Clinical Trial of ZVS203e in Subjects With Retinitis Pigmentosa Associated With RHO Mutation
Latest Information Update: 08 May 2025
At a glance
- Drugs ZVS 203e (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chigenovo
Most Recent Events
- 08 May 2025 New trial record